The Dynamics of Antimicrobial Resistance among Enterobacteriaceae Isolates to Ceftazidime in Benghazi, Libya

Abstract

Enterobacteriaceae are among the most typical pathogens, causing a broad range of community-acquired and healthcare-associated infections and associated with substantial worsening of patients' quality of life and increased mortality. Ceftazidime is a combination of the third-generation intravenously administered cephalosporin ceftazidime and the novel non-β-lactam b-lactamase inhibitor avibactam. This study aimed to explore the invitro activity of ceftazidime against bacterial isolates from various clinical samples. The samples collected from the wounds pus, burn; medical devices, tips and blood from male and female patients in the age group of 3 to 86 years with clinical characteristics suspected to be infected and are transmitted to the Microbiology Department of Al-Saleem laboratory, Benghazi, Libya between October 2021 and January 2022. The swab infection rate was higher in males than in females. The majority of the subjects (19.6%) were in the 40-49 years old group. E. coli and klebsiella spp were the most prevalent pathogens of pus swab contagion respectively. The most bacteria found were E. coli, 57 isolates (32.6%) and Klebsiella spp 18 isolates (19.6%). The susceptibility test for ceftazidime found that 30.4% of E. coli isolates were susceptible to ceftazidime. The results of this study indicate that Gram-negative bacteria are less sensitive to ceftazidime. Almost isolated strains showed a ratio of intermediate to ceftazidime. Therefore, Ceftazidime is not recommended for use as an Empirical treatment.